ライフサイエンスコーパス: glycated

1 Forty-five glycated, 48 advanced glycation endproduct (AGE-) modifi

2 herapeutic approaches against neurotoxic CEL-glycated Abeta1-42.

3 eins, such as glycated hemoglobin (HbA1c) or glycated albumin (GA) in the blood, are essential indica

4 an HbA1c in meta-analysis (P = 0.0225), mean glycated albumin (P = 0.0029), and glyoxal hydroimidazol

5 We measured glycated albumin and fructosamine in 11 104 participants

6 ifferences were found in the relationship of glycated albumin and fructosamine levels with the mean g

7 Fructosamine and glycated albumin are markers of short-term glycemic cont

8 We found that fructosamine and glycated albumin were associated with vascular outcomes

9 baseline concentrations of fructosamine and glycated albumin were significantly associated with each

10 e evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, is

11 , glycated hemoglobin (HbA1c), fructosamine, glycated albumin), and a latent variable for kidney func

12 monitoring and compared by race with HbA1c, glycated albumin, and fructosamine values.

13 FK is the epsilon-fructosyl amino acid from glycated albumin, another glycated protein, whereas gluc

14 d fasting glucose, insulin, adiponectin, and glycated albumin, as well as body mass index (BMI), use

15 enabling separation of positional isomers of glycated alpha- and beta-chains on the intact level.

16 The percentage of glycated alpha-Hb and beta-Hb was calculated from the mi

17 case that repairs methylglyoxal- and glyoxal-glycated amino acids and proteins by acting on early gly

18 nes, arginines, and lysines (the three major glycated amino acids) of serum albumin, glyceraldehyde-3

19 nchmark dataset was extracted containing 235 glycated and 303 non-glycated lysine residues.

20 based on support vector machine, to predict glycated and non-glycated lysine residues using structur

21 The proposed predictor manages to classify glycated and non-glycated lysine residues with promising

22 nine sites, as well as by converting already-glycated arginine residues into citrulline.

23 A second glycated beta-Hb isomer that is partially resolved from

24 The values for glycated beta-Hb were found to correlate well with the H

25 n is achieved between alpha-Hb, beta-Hb, and glycated beta-Hb.

26 ected in extracted ion electropherograms for glycated beta-Hb.

27 Measurement of glycated blood proteins, particularly glycated hemoglobi

28 glycated chaperone-client complexes than in glycated but uncomplexed protein mixtures.

29 backbone conformation from A to B form when glycated, but does not induce any final transition in DN

30 Proteins were glycated by incubation with sugars (glucose, methylglyox

31 protein isolates that had been denatured and glycated by thermal treatment.

32 inking AGEs were significantly higher in the glycated chaperone-client complexes than in glycated but

33 Glycated collagen 1 and AGE-modified ECM regulate adipoc

34 en fibrils and, using KFM and FLiM, that R5P-glycated collagen fibrils have a more negative surface c

35 e extracellular matrix structure surrounding glycated collagen fibrils.

36 indicated the formation of hydrolysates and glycated compounds with different molecular weight distr

37 on products (MRPs), protein hydrolysates and glycated compounds.

38 To prepare glycated cowpea protein isolate (GCPI) the cowpea flour

39 By using ESI-QTOF-MS technique, formation of glycated cytochrome C containing up to 12 glucose moieti

40 terial mutants displayed increased levels of glycated DNA and RNA and exhibited strong mutator phenot

41 e for a rapid and reliable identification of glycated DNA in a reagent-free manner.

42 in contrast to guanine oxidation repair, how glycated DNA is repaired remains undetermined.

43 ws a clear discrimination between native and glycated DNA samples.

44 depleted cells displayed increased levels of glycated DNA, DNA strand breaks, and phosphorylated p53.

45 e process where proteins accumulate advanced glycated end products (AGEs).

46 indicated a significant decrease in advance glycated end products and protection against glycoxidati

47 Hyperglycemia and exposure to advanced glycated end products inactivated MFG-E8, recognizing a

48 lysates showed reduced fluorescence advanced glycated end-products (AGE) and a reduced amount of alph

49 insulin signaling, accumulation of advanced glycated end-products, altered autophagy, changes in myo

50 e-associated molecular patterns and advanced glycated endproducts and can trigger cell activation.

51 Amadori rearrangements and the free and mono-glycated guanidine also formed imidazolinone derivatives

52 diabetes remission at 2 years, defined as a glycated haemaglobin A1c (HbA1c) concentration of 6.5% o

53 ive treatments for type 2 diabetes, lowering glycated haemoglobin (HbA(1c)) and weight, but are curre

54 years, diagnosed with type 2 diabetes with a glycated haemoglobin (HbA(1c)) concentration of 7.5% or

55 Glycated haemoglobin (HbA(1c)) is considered the gold st

56 erol <=4 mmol/L, triglycerides <=1.7 mmol/L, glycated haemoglobin (HbA1c) <=53 mmol/mol (<=7.0%), sys

57 more, and remission of diabetes, defined as glycated haemoglobin (HbA1c) of less than 6.5% (<48 mmol

58 lucose (FBS), random blood glucose (RBS), or glycated haemoglobin (HbA1c) were reported.

59 Mean changes in glycated haemoglobin (HbA1c), and mean changes in fastin

60 lthough associations between multimorbidity, glycated haemoglobin (HbA1c), and mortality in people wi

61 nge glucose and insulin measures, as well as glycated haemoglobin (HbA1c), are used to diagnose and m

62 and intensification: age, sex, deprivation, glycated haemoglobin (HbA1c), body mass index (BMI), smo

63 lso associated with improvements in glucose, glycated haemoglobin (HbA1c), weight, waist circumferenc

64 n delivery (pump or injections) and baseline glycated haemoglobin (HbA1c).

65 density-lipoprotein cholesterol (HDL-C), and glycated haemoglobin (HbA1c).

66 eins [LDL and HDL], triglycerides [TGs], and glycated haemoglobin [HbA1c]).

67 abetes at high cardiovascular risk with high glycated haemoglobin A(1c) (HbA(1c)) concentrations.

68 prior to enrolment, and centrally confirmed glycated haemoglobin A1c (HbA(1c)) of 48-58 mmol/mol (6.

69 The primary outcome was a change in glycated haemoglobin A1c (HbA1c) from baseline to week 2

70 function, lipid profile, glucose tolerance, glycated haemoglobin A1c, salivary cortisol, sitting hei

71 , systolic and diastolic blood pressures and glycated haemoglobin in the 1958 British Birth Cohort (1

72 and additional cardiovascular risk factors, glycated haemoglobin of up to 9.5% (80 mmol/mol) on a ma

73 Changes in fasting glucose and glycated haemoglobin were not different between groups a

74 The changes in glycated haemoglobin, as the primary outcome, in the pro

75 = 32), and were correlated with the level of glycated haemoglobin, glycaemic level, and time of disea

76 iles (longer duration of diabetes and higher glycated haemoglobin, non-HDL cholesterol, and waist-to-

77 least two creatinine, thyrotropin, calcium, glycated haemoglobin, or lithium measurements between Oc

78 sure, body-mass index, total cholesterol and glycated-haemoglobin levels.

79 It was observed that patients with elevated glycated Hb levels also had higher levels of HSA glycati

80 Quantification of glycated Hb was in good correlation with the results obt

81 In clinical routine analysis of glycated Hb, sequence variants or other Hb proteoforms c

82 nctive test lines when challenged with HbA0, glycated HbA0 and HbA2.

83 points, P<0.001) and had similar control of glycated hemoglobin (0.3 percentage points, P=0.63).

84 ss index (47.6+/-9.3 to 36.7+/-7; P<0.0001), glycated hemoglobin (6.7+/-1.5 to 5.8+/-0.6; P<0.0001),

85 liflozin group than in the placebo group for glycated hemoglobin (difference, -0.46 percentage points

86 Improved glycated hemoglobin (Hb A1c) delays the progression of m

87 oad glucose (PG), 2-h postload insulin (PI), glycated hemoglobin (Hb A1c), and homeostasis model asse

88 Glycated hemoglobin (HbA(1c)) is an important measure of

89 08) while controlling for age, sex, baseline glycated hemoglobin (HbA(1c)), baseline CMT, baseline VA

90 es diagnosis, serum fasting glucose (FG) and glycated hemoglobin (HbA(1c)), were estimated to be 51-6

91 om among 321 people with type 2 diabetes and glycated hemoglobin (HbA1c) >58 mmol/mol.

92 ype 2 diabetes were recruited: subjects with glycated hemoglobin (HbA1c) </=7% and subjects with HbA1

93 ; betaPFOA=1.71 pM; 95% CI: 0.72, 2.71), and glycated hemoglobin (HbA1c) (betaPFOS=0.03%; 95% CI: 0.0

94 ) concentration (-37.0 mg/dL; P < 0.001) and glycated hemoglobin (HbA1c) [-0.97% (-10.6 mmol/mol); P

95 a significant difference in postintervention glycated hemoglobin (HbA1c) between the arms (P = 0.007)

96 ulinemia, decreased C-peptide, and increased glycated hemoglobin (HbA1c) compared with sham-operated

97 d the association between food label use and glycated hemoglobin (HbA1c) concentrations.

98 After 12 months, glycated hemoglobin (HbA1c) decreased from 10.3+/-2.4% t

99 has been developed for the determination of glycated hemoglobin (HbA1c) in human blood samples.

100 The level of Glycated hemoglobin (HbA1c) is accordingly examined for

101 Glycated hemoglobin (HbA1c) is used to diagnose type 2 d

102 ex, waist circumference, fat percentage, and glycated hemoglobin (HbA1c) level were recorded chairsid

103 n leakage area at month 36 (P = 0.0137), and glycated hemoglobin (HbA1c) levels at month 36 (P = 0.00

104 (20-50 U) and metformin (>/=1500 mg/d) with glycated hemoglobin (HbA1c) levels of 7% to 10% and a bo

105 nfluence of periodontal status on changes of glycated hemoglobin (HbA1c) levels of patients with type

106 igated OCT-A parameters with DM duration and glycated hemoglobin (HbA1c) levels were evaluated among

107 Glycated hemoglobin (HbA1c) levels were measured, and pr

108 2 spectral domain OCT (SD-OCT) tests, and 2 glycated hemoglobin (HbA1c) measures over time with a mi

109 DM prevalence was estimated using laboratory glycated hemoglobin (HbA1c) or fasting plasma glucose in

110 Glycated proteins, such as glycated hemoglobin (HbA1c) or glycated albumin (GA) in

111 hievement of good glycemic control, of which glycated hemoglobin (HbA1c) remains the standard clinica

112 An immunoassay for detection of glycated hemoglobin (HbA1c) that can reveal a patient's

113 in or loss and glycemic control (assessed by glycated hemoglobin (HbA1c) values) in patients from the

114 In multivariable analyses, glycated hemoglobin (HbA1c) was inversely associated wit

115 Higher levels of glycated hemoglobin (HbA1c) were associated with all-cau

116 rmined for fasting glucose, fasting insulin, glycated hemoglobin (HbA1c), and homeostasis model asses

117 tion of high- compared with low-fat dairy on glycated hemoglobin (HbA1c), body weight, and cardiovasc

118 The relationship between delayed GE and glycated hemoglobin (HbA1c), complications of DM, and ga

119 eplacement of other sugars and its effect on glycated hemoglobin (HbA1c), fasting blood glucose, insu

120 agnostic accuracies of random blood glucose, glycated hemoglobin (HBA1c), fructosamine, and Homeostas

121 glycemia (diabetes status, fasting glucose, glycated hemoglobin (HbA1c), fructosamine, glycated albu

122 triacylglycerol (TG), fasting glucose (FG), glycated hemoglobin (HbA1c), insulin resistance (HOMA-IR

123 and at follow-up, was associated with higher glycated hemoglobin (HbA1c), insulin, HOMA-IR, triglycer

124 ent of glycated blood proteins, particularly glycated hemoglobin (HbA1c), is an important diagnostic

125 Blood glycated hemoglobin (HbA1c), reflecting the average bloo

126 ed with the diabetes GRS on fasting insulin, glycated hemoglobin (HbA1c), the homeostasis model asses

127 Measurement of glycated hemoglobin (HbA1c), the most widely accepted in

128 blood pressure (BP), fasting blood glucose, glycated hemoglobin (HbA1c), triglyceride levels, trigly

129 led trials (RCTs) that assessed the outcomes glycated hemoglobin (HbA1c), weight, body mass index (BM

130 sensor was developed for the recognition of glycated hemoglobin (HbA1c).

131 body mass index (in kg/m(2)): 34.6 +/- 4.3; glycated hemoglobin (HbA1c): 7.3 +/- 1.1%; duration of d

132 n [n = 136; mean +/- SD age: 12.8 +/- 2.6 y; glycated hemoglobin (HbA1c): 8.1% +/- 1.0%; 69.1% using

133 .7%) was associated with a reduction in mean glycated hemoglobin (HbA1c, -1.3 +/- 1.8%, P < 0.001), f

134 In 2006, 56% of incident cases had a glycated hemoglobin (hemoglobin A1c) test as one of the

135 Levels of blood glucose/glycated hemoglobin (International Federation of Clinica

136 How these risks vary with glycated hemoglobin (or hemoglobin A1c [HbA1c]) levels i

137 ion was associated with a higher increase in glycated hemoglobin (P = 0.027).

138 luble leptin receptor (reduction of 43%) and glycated hemoglobin (reduction of 28%).

139 97 individuals >=40 and <=80 years old with glycated hemoglobin 6.5% to 10.0%, known coronary artery

140 y; median (IQR), 10 (5-9) y of T2D duration; glycated hemoglobin 7.0% +/- 0.8%; body mass index (in k

141 8 of whom had poor glycemic control (average glycated hemoglobin [HbA1c] >/=8% during the year) while

142 tensive glycemic control in type 2 diabetes (glycated hemoglobin [HbA1c] level <7%) is an established

143 cose [RBG], fasting blood glucose [FBG], and glycated hemoglobin [HbA1c]) and survival in all lung tr

144 fication by sex, history of ischemic stroke, glycated hemoglobin A(1c), body mass index, blood pressu

145 g plasma glucose >/=200 mg/dl (11.1 mmol/l), glycated hemoglobin A1c (HbA1c) >6.5%, self-reported phy

146 se [FCG] level, 2-hour CG [2-hCG] level, and glycated hemoglobin A1c [HbA1c] level) at enrollment, an

147 agnosis, sex, race/ethnicity, net worth, and glycated hemoglobin A1c fraction (HbA1c).

148 While adjusting for duration of diabetes, glycated hemoglobin A1c level, and other factors, we fou

149 The mean (SD) glycated hemoglobin A1c of the 50 patients (26 men and 2

150 ciation of baseline waist circumference with glycated hemoglobin A1c reduction is likely due to selec

151 The only significant predictor of glycated hemoglobin A1c reduction was waist circumferenc

152 are well-adhered to, whereas guidelines for glycated hemoglobin A1c testing for type 2 diabetes mell

153 s largely determined by assessment of HbA1c (glycated hemoglobin A1c) levels, which poorly reflects d

154 Weight, BMI, glycated hemoglobin A1c, fasting glucose, and insulin we

155 We collected data on histories of patients' glycated hemoglobin A1c, hypertension, hyperlipidemia, s

156 tions, pain (numeric rating scale), level of glycated hemoglobin A1c, level of C-reactive protein, bo

157 s there exists a direct relationship between glycated hemoglobin and cardiovascular disease (CVD), cl

158 y is to investigate the relationship between glycated hemoglobin and circulating levels of interleuki

159 All participants were screened for DM using glycated hemoglobin and fasting plasma glucose at TB tre

160 ic red blood cells correlates with levels of glycated hemoglobin and that the mechanical properties o

161 of Germany or Austria), body mass index, and glycated hemoglobin as covariates were used to account f

162 iculated thrombocytosis that correlates with glycated hemoglobin as well as increased plasma S100A8/A

163 ing age, absence of epiretinal membrane, and glycated hemoglobin below 9 as predictive of DR ultra-re

164 ears after baseline on the basis of either a glycated hemoglobin concentration of at least 6.5% or us

165 studies that have demonstrated reductions in glycated hemoglobin concentration.

166 ng an extended interval of separation of the glycated hemoglobin curves (hazard ratio, 0.83; 95% CI,

167 ed 1791 participants), the separation of the glycated hemoglobin curves between the intensive-therapy

168 nly during the prolonged period in which the glycated hemoglobin curves were separated.

169 s improved, for example, fasting glucose and glycated hemoglobin decreased from 6.1 to 5.4 mmol/mol a

170 Glycated hemoglobin decreased significantly from 8.2 +/-

171 h both incidence of T2D and increased plasma glycated hemoglobin in individuals without T2D, providin

172 and with low HDL concentrations and elevated glycated hemoglobin in obese and diabetic patients.CCK r

173 closures do not affect health in general, 2) glycated hemoglobin is insensitive to local foreclosure

174 52.5 vs 54.8 years), BMI (45.1 vs 42.6), and glycated hemoglobin level (7.1% vs 7.1%).

175 wer; 95% CI, 24 to 51; P<0.001) and the mean glycated hemoglobin level (difference, -0.3%; 95% CI, -0

176 , 1.02; 95% CI, 1.01-1.04) and knowing one's glycated hemoglobin level (odds ratio, 2.00; 95% CI, 1.3

177 , sulfonylurea) with stable body weight, and glycated hemoglobin level 7.0% to 10.0%.

178 uration of diabetes 34.6 years, and the mean glycated hemoglobin level 8.2%.

179 nd point was the change from baseline in the glycated hemoglobin level after 26 weeks.

180 The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 perce

181 index greater than the 85th percentile and a glycated hemoglobin level between 7.0 and 11.0% if the p

182 The primary end point was the change in glycated hemoglobin level from baseline to week 26.

183 of the primary efficacy end point, the mean glycated hemoglobin level had decreased by 0.64 percenta

184 The primary end point was a glycated hemoglobin level lower than 7.0% at week 24, wi

185 n, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% with no severe

186 with 4.3% over 3 years among patients with a glycated hemoglobin level of 10%.

187 was 1.0% over 5 years among patients with a glycated hemoglobin level of 6%, as compared with 4.3% o

188 The primary outcome was a glycated hemoglobin level of 6.0% or less with or withou

189 diagnosis of obstructive sleep apnea, with a glycated hemoglobin level of 6.5-8.5%, and an oxygen des

190 ients younger than 55 years of age who had a glycated hemoglobin level of 6.9% or less (</=52 mmol pe

191 ng those younger than 55 years of age with a glycated hemoglobin level of 6.9% or less, as compared w

192 l study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of

193 ed hemoglobin level score [calculated as the glycated hemoglobin level plus 4 times the insulin dose]

194 of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%.

195 e patient's current state of retinopathy and glycated hemoglobin level reduced the frequency of eye e

196 esponse (defined as an insulin dose-adjusted glycated hemoglobin level score [calculated as the glyca

197 r mean percentage reduction from baseline in glycated hemoglobin level than did patients who received

198 e estimated mean change from baseline in the glycated hemoglobin level was -1.33 percentage points in

199 The mean (SD) glycated hemoglobin level was 7.4% (0.5%).

200 At 24 months, the mean glycated hemoglobin level was 7.5+/-1.2% in each group,

201 similar in the two groups; the mean baseline glycated hemoglobin level was 8.09% in the icodec group

202 iabetes was 16.4 years, and the mean (+/-SD) glycated hemoglobin level was 8.4+/-1.7%; 83.9% of the p

203 s 16.1 years (range, 2-36 years), and median glycated hemoglobin level was 8.8% (IQR, 7.4%-10%).

204 s was 49+/-8 years, 66% were women, the mean glycated hemoglobin level was 9.2+/-1.5%, and the mean B

205 hich patients with type 2 diabetes mellitus (glycated hemoglobin level, >=7%), chronic kidney disease

206 ucose load, 140 to 199 mg per deciliter; and glycated hemoglobin level, 5.7 to 6.4%) and no diagnosti

207 type 2 diabetes was inadequately controlled (glycated hemoglobin level, 7.0 to 9.5%) while taking met

208 etes had poor glycemic control (mean [+/-SD] glycated hemoglobin level, 9.0+/-2.4%), and the rates of

209 s >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that t

210 itional end points included insulin use, the glycated hemoglobin level, the number of hypoglycemic ev

211 points included the change from baseline in glycated hemoglobin level, weight, systolic blood pressu

212 C-peptide levels, insulin requirements, and glycated hemoglobin level.

213 lycemia, and, in adults, resulted in a lower glycated hemoglobin level.

214 1.13; P = .003) for each unit of increase in glycated hemoglobin level.

215 counting for glycemic control in the form of glycated hemoglobin level.

216 significant difference between the groups in glycated hemoglobin level.

217 t did not continue after equalization of the glycated hemoglobin levels (hazard ratio, 1.26; 95% CI,

218 f 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean differenc

219 The phenomenon of a discrepancy between glycated hemoglobin levels and other indicators of avera

220 loop group and 23 to the control group); the glycated hemoglobin levels at baseline ranged from 5.7 t

221 The difference in glycated hemoglobin levels between the intensive-therapy

222 previously been found to reduce glucose and glycated hemoglobin levels in humans.

223 e fully attenuated after adjustment for mean glycated hemoglobin levels over the entire follow-up.

224 Glycated hemoglobin levels were lower with pump therapy

225 Secondary outcomes included glycated hemoglobin levels, insulin dose, and body mass

226 men, C-reactive protein, lipoprotein(a), and glycated hemoglobin levels.

227 progression was also closely related to mean glycated hemoglobin levels.

228 al history, antidiabetic medication use, and glycated hemoglobin levels.

229 c blood pressures, and high triglyceride and glycated hemoglobin levels.

230 ere among metabolic surgery patients (higher glycated hemoglobin levels; greater percentage of insuli

231 amer-based microfluidic system for automatic glycated hemoglobin measurements.

232 /m(2)) of 39.2 (95% CI: 35.2, 43.3) and mean glycated hemoglobin of 5.3% (95% CI: 4.9%, 5.6%), were s

233 Adults with type 2 diabetes, glycated hemoglobin of 6.5% to 8.5%, and elevated cardio

234 We used admission glycated hemoglobin to estimate premorbid baseline blood

235 lar disease (CVD), clinical trials targeting glycated hemoglobin to near-normal levels using intensiv

236 ological factors assessed, insulin index and glycated hemoglobin values explained 15% and 16% of the

237 mm Hg; -9.0, -2.7 mm Hg) diets, and reduced glycated hemoglobin with the Mediterranean diet (-0.8 mm

238 rs are modestly effective in reducing HbA1c (glycated hemoglobin) ( approximately 0.5%) and while the

239 inal pro-B-type natriuretic peptide), HbA1C (glycated hemoglobin), and systolic blood pressure were o

240 Thirteen people with T2DM (glycated hemoglobin, 6.9+/-1.0%) and 12 age-matched heal

241 an age, 64.0 years; 2414 [39.9%] women; mean glycated hemoglobin, 7.2%; median duration of diabetes,

242 ysis (OCT) over a 4-y period, independent of glycated hemoglobin, age, and sex.

243 syndrome (69.2 vs. 51.9%), fast glycemia and glycated hemoglobin, albuminuria, triglycerides and uric

244 cholesterol, triglycerides, blood pressure, glycated hemoglobin, and fasting glucose and report the

245 ar reductions in insulin, insulin C-peptide, glycated hemoglobin, and homeostasis model assessment of

246 ymptoms and changes in the levels of lipids, glycated hemoglobin, and prolactin were similar in the t

247 e intervention group had significantly lower glycated hemoglobin, fasting plasma glucose, plaque inde

248 cant between-group differences were found in glycated hemoglobin, HDL-cholesterol, or triglyceride co

249 justment for metabolic biomarkers, including glycated hemoglobin, high-density lipoprotein cholestero

250 rly high-density lipoprotein cholesterol and glycated hemoglobin, led to a greater degree of attenuat

251 For every 1% higher glycated hemoglobin, left ventricular mass was higher by

252 cident CKD included BP >140/90 mm Hg, higher glycated hemoglobin, lower baseline eGFR, and higher bas

253 ptical coherence tomography, blood pressure, glycated hemoglobin, medications, and changes in such pa

254 positive correlation of chemerin with IL-6, glycated hemoglobin, sampled-site clinical attachment le

255 adjusting for age, waist-to-hip ratio (WHR), glycated hemoglobin, smoking, education, and grip streng

256 e foreclosure rate per census-block group on glycated hemoglobin.

257 block group in the prior year and changes in glycated hemoglobin.

258 een the study groups were seen for change in glycated hemoglobin.

259 s-related traits such as fasting glucose and glycated hemoglobin.

260 f signals while varying concentration of the glycated hemoglobin.

261 corresponding reduction in the percentage of glycated-hemoglobin to levels similar to lean, healthy m

262 d by measurement of the cutoff ratio between glycated hemoglobins (HbA1c) and total hemoglobin (Hb),

263 ntified peptides in the enriched fraction as glycated, high sensitivity for detection of glycated pep

264 1c levels did not have the highest levels of glycated HSA.

265 of glycated peptides quantified in in vitro glycated human plasma increased more than 3-fold using t

266 and modified DNA aptamers specifically bound glycated human serum albumin (GHSA), which is an interme

267 The glycated hydrolysates showed reduced fluorescence advanc

268 We chemically synthesized glycated IAPP (AGE-IAPP) to mimic the consequence of thi

269 We also noted a decrease in glycated lysine residues in collagen, indicating that th

270 vector machine, to predict glycated and non-glycated lysine residues using structural properties of

271 edictor manages to classify glycated and non-glycated lysine residues with promising results consiste

272 xtracted containing 235 glycated and 303 non-glycated lysine residues.

273 trast, only 168 polypeptides contained early glycated lysines, which did not resemble the sites of ad

274 YajL could repair methylglyoxal- and glyoxal-glycated nucleotides and nucleic acids.

275 e 2D-LC-HCD-MS/MS platform for comprehensive glycated peptide quantification.

276 line platform to human plasma identified 376 glycated peptides from 10 mug of protein digests.

277 The number of glycated peptides quantified in in vitro glycated human

278 glycated, high sensitivity for detection of glycated peptides with LOD and LOQ at 1.2 and 2.4 pg, re

279 ility with interday CVs < 20% for 80% of the glycated peptides.

280 ool for identification and quantification of glycated peptides.

281 rabidopsis thaliana The absence of the early glycated precursors of the AGE-modified protein residues

282 oducible online 2D platform is promising for glycated protein analysis of complex clinical samples.

283 n in exposed splenocyte, were evident in the glycated protein treated mice as compared to its native

284 Thereafter, allergic behaviour of this glycated protein was compared with its native form, usin

285 The reduced allergenicity of glycated protein was observed as lesser allergic phenoty

286 yl amino acid from glycated albumin, another glycated protein, whereas glucose is naturally present a

287 Glycated proteins are emerging as good indicators for di

288 Although the patterns of glycated proteins were only minimally influenced by plan

289 hree aging-specific and eight differentially glycated proteins, four of which were modified in cataly

290 Glycated proteins, such as glycated hemoglobin (HbA1c) o

291 However, the platform for analysis of glycated proteome has been relatively less well establis

292 -related changes in the Arabidopsis thaliana glycated proteome, including the proteins affected and s

293 to 12 glucose moieties were observed, while glycated species containing 6 and 8 glucose moieties wer

294 rameters with the levels of glycosylated and glycated species in a series of small scale experiments,

295 proteoforms, including positional isomers of glycated species in a single run.

296 The glycated species of cytochrome C, lysozyme, and beta-cas

297 Cytochrome C had multiple charges in non-glycated state, primarily changing from +13 to +17 posit

298 In its absence, NRF2 is extensively glycated, unstable, and defective at binding to small MA

299 ocess (ISP) was hydrolysed with Alcalase and glycated with glucosamine (GlcN) at moderate temperature

300 rmal stability and antioxidative capacity of glycated WP were increased, especially in the presence o